Yazar "Kalkanli, S" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Factor V Leiden mutation in venous thrombosis in southeast Turkey
    (Sage Publications Inc, 2006) Kalkanli, S; Ayyildiz, O; Tiftik, N; Batun, S; Isikdogan, A; Ince, H; Tekes, S
    Venous thrombosis (VT) is a common disease, with an annual incidence in the general population of approximately I per 1,000. Factor V Leiden mutation (G1691A) (FVL) is the most common risk factor in venous thrombosis. The prevalence of FVL for thrombosis varies greatly in different regions of the world. FVL mutation has been identified both by conventional method and fluorescence resonance energy transfer (FRET) with the LightCycler. Sixty-one patients with VT, different in age and sex, were consecutively entered into this study to assess the prevalence of FVL in VT in southeast Turkey. FVL mutation was found in 24.6% (15/61). Fourteen individuals were heterozygous and I homozygous, a rate of 22.9% and 1.6%, respectively. In conclusion, the authors suggest that FVL mutation is common in patients with venous thrombosis in southeast Turkey.
  • [ X ]
    Öğe
    Molecular basis of ?-Thalassemia mutations in Diyarbakir in the southeastern region of Turkey
    (Marcel Dekker Inc, 2003) Ince, HH; Ayyildiz, O; Kalkanli, S; Batun, S; Muftuoglu, E
    [Abstract Not Available]
  • [ X ]
    Öğe
    Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey
    (Springer, 2004) Ayyildiz, O; Kalkanli, S; Batun, S; Aybak, M; Isikdogan, A; Tiftik, N; Bolaman, Z
    Venous thrombosis (VT) is a common disease, with an annual incidence in the general population of approximately 1 per 1000. The prevalence of genetic risk factors for thrombosis varies greatly in different parts of the world. Prothrombin G20210A (PT G20210A) gene mutation has been recently identified as a common risk factor in venous thrombosis. Sixty-one patients with VT, differing in age and sex, and 340 healthy subjects were consecutively enrolled into our study to determine the prevalence of PT G20210A in VT and in the healthy population of the southeast of Turkey. The mutation was identified with fluorescence resonance energy transfer (FRET) with the LightCycler polymerase chain reaction. The PT G20210A mutation was found to be 6.5% (4/61) in the VT group and 1.2% (4/340) in the healthy group (P = 0.021). Three patients with VT had a heterozygous PT G20210A mutation, and the other patient with VT had both Factor V Leiden and PT G20210A mutations. We showed that this method may be used safely for detection of the PT G20210A gene mutation, and the prevalence of PT G20210A mutation is significantly higher in patients with VT than in the healthy population in the southeast of Turkey.